Free Newsletter
Vaccine a success for human-to-human H5N1 case
A case of human-to-human transmission of bird flu has been confirmed in China, but authorities say it is another instance where the spread of the disease has been limited to a close blood relative. And in this case an experimental H5N1 vaccine demonstrated that it could possibly vanquish the lethal virus, which could have significant implications for the development of a pandemic vaccine.
A father caring for a sick son--who died--contracted the illness and was treated unsuccessfully with antivirals. Then he was given plasma drawn from a woman who had received an experimental bird flu vaccine that had been made from whole, killed H5N1. The vaccine was made by Sinovac from a 2004 Vietnamese strain of the disease. If researchers can show that the recovery was linked to the vaccine, the whole virus vaccine could prove a key to spurring immunity to a range of possible mutations of H5N1.
Late last year another bird flu patient in China recovered after being given plasma from a survivor of bird flu, pointing to the role that therapeutic antibodies could play in a fight against a potential pandemic.
- read the report in New Scientist
- check out the story in the Independent
ALSO: Indian officials are fighting a fresh outbreak of H5N1 in birds. Report
Related Articles:
Sinovac to produce H5N1 vaccine. Report
Sinovac to mass produce bird flu vaccine. Report
GSK bird flu vaccine provides more positive data. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FierceBiotech Research email newsletter for FREE!
Be the first to comment